Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin chemoradiation versus radiotherapy alone for muscle-invasive bladder cancer
ACTRN12607000041459Phase 3Completed
- Sponsor
- Kumar Gogna
- Start
- Oct 2002
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cisplatin in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Kumar Gogna. Primary endpoint: Invasive local failure. Started Oct 2002; status: completed.
02
Drugs
cisplatin
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ACTRN12607000041459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000041459.